BioSpace News Archive

Rezolute, Inc. today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.

University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test.

Edgewise Therapeutics, Inc. today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy (Becker) and for the treatment of Duchenne muscular dystrophy (Duchenne).

Silo Pharma, Inc. today announced positive data in the final validation report from the recent pharmacokinetic (PK) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD).

Masimo (NASDAQ: MASI) will release first quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, May 7, 2024.

Tarsus Pharmaceuticals, Inc. announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP.

Artelo Biosciences, Inc. today announced the publication of an article, “The emerging role of fatty acid binding protein 7 (FABP7) in cancers,” in Drug Discovery Today, a peer-reviewed journal.

GeneDx, a leader in delivering improved health outcomes through genomic insights, announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.

AAVantgarde Bio announces the publication of an abstract accepted as an oral presentation submitted to The American Society of Gene & Cell Therapy 27th Annual Meeting, to be held May 7-11 in Baltimore.

Medivir AB announced an update from a Type C meeting with the FDA, regarding the company’s plans for a global phase 2b study and opening of an IND for fostroxacitabine bralpamide in the US.